⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for EXOme Rare Cancers in Children (EXOCARE)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: EXOme Rare Cancers in Children (EXOCARE)

Official Title: An Investigation of Susceptibility Genes for Rare Cancers in Children by Exome Sequencing

Study ID: NCT03472807

Study Description

Brief Summary: Other than high-dose radiation and previous chemotherapy, few strong risk factors have been identified as causes of childhood cancer. Geneticists estimate that 5 to 10% of all cancers diagnosed during the paediatric period occur in children born with a genetic mutation, increasing their lifetime risk of neoplasia. Such genetic risk is higher in children with congenital anomalies and specific genetic syndromes. Some germline genetic alterations are well known (e.g. P53 protein (P53), Neurofibromatosis type 1(NF1)), however many children with none of these mutations have clinical presentations that strongly suggest the involvement of a genetic predisposition. Comprehensive genetic testing for all such patients is an important factor for improving disease surveillance. Such opportunities are now available thanks to whole exome sequencing (WES). In oncology, an important clinical application of WES will be to routinely identify mutations associated with inherited cancer predispositions and to guide cancer risk-management decisions. Our project is a national translational multicenter genetics study aimed at identifying genes involved in paediatric cancer predisposition by WES in a very select population of children with both developmental delay and cancer. Our project relies on the TED register (Tumeur Et Développement), an initiative by the French organisation SFCE (Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent) involving 30 child cancer units in France. This database includes the information of more than 500 paediatric cancer patients with congenital abnormalities. The investigators plan to sequence the germline and tumour exome of 100 patients with developmental delay in a trio-design consisting of 300 people and 100 tumours. The investigators believe that the ExoCaRe project will provide answers to the genetic origins of certain particular childhood cancers. The ExoCaRe project relies on a genetic study to identify genetic risk factors for rare forms of childhood cancer and aims to establish more personalised treatment. It is aimed at improving genetic counselling for families and will be fully integrated in the genetic counselling process. The information provided by our study will be used to improve the management approach to an initial cancer by clarifying the risks of other cancers in related families. The investigators hope to identify new germline genes predisposing to cancer that will be of interest in understanding tumour biology.

Detailed Description: -Primary objective : Our aim is to identify new mutations and genes involved in paediatric cancer predisposition associating developmental delay by WES of a sub-cohort of patients included in the TED database. -Secondary objectives : 1. Describe inherited predisposition to cancer. 2. Improve genetic counselling processes. 3. Initiate clinical exome sequencing in childhood cancer treatment.

Keywords

Eligibility

Minimum Age:

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University Hospital of Amiens, Amiens, , France

University Hospital of Angers, Angers, , France

Cancer Center Bergonie Institut, Bordeaux, , France

University Hospital of Bordeaux, Bordeaux, , France

University Hospital of Brest, Brest, , France

University Hospital of Clermont Ferrand, Clermont-Ferrand, , France

University Hospital of Dijon, Dijon, , France

University Hospital of Grenoble, Grenoble, , France

University Hospital of Lille, Lille, , France

University Hospital of Limoges, Limoges, , France

Institut of Haematology and Paediatric Oncology of Lyon, Lyon, , France

University Hospital of Marseille, Marseille, , France

University Hospital of Montpellier, Montpellier, , France

University Hospital of Nancy, Nancy, , France

University Hospital of Nantes, Nantes, , France

University Hospital of Nice, Nice, , France

Institut Curie, Paris, , France

University Hospital of Kremlin Bicetre, Paris, , France

University Hospital of Necker, Paris, , France

University Hospital of Trousseau, Paris, , France

University Hospital of Rennes, Rennes, , France

University Hospital of Rouen, Rouen, , France

University Hospital of Saint Etienne, Saint-Étienne, , France

University Hospital of Strasbourg, Strasbourg, , France

University Hospital of Tours, Tours, , France

Institut Gustave Roussy, Villejuif, , France

University Hospital of Saint Denis de La Reunion, Saint-Denis, , Réunion

Contact Details

Name: Isabelle PELLIER, Pr

Affiliation: UH Angers

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: